| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cholangiocarcinoma | 10 | 2024 | 493 | 3.910 |
Why?
|
| Bile Duct Neoplasms | 8 | 2024 | 493 | 3.130 |
Why?
|
| Melanoma | 26 | 2023 | 5317 | 2.140 |
Why?
|
| Proto-Oncogene Proteins B-raf | 12 | 2023 | 1283 | 1.820 |
Why?
|
| Oncogenes | 6 | 2021 | 673 | 1.110 |
Why?
|
| Isocitrate Dehydrogenase | 4 | 2024 | 480 | 0.930 |
Why?
|
| Colorectal Neoplasms | 9 | 2022 | 3578 | 0.860 |
Why?
|
| Mutation | 23 | 2024 | 15179 | 0.850 |
Why?
|
| Melanoma, Experimental | 2 | 2015 | 368 | 0.830 |
Why?
|
| Cyclin-Dependent Kinase 4 | 5 | 2022 | 198 | 0.770 |
Why?
|
| Disease Models, Animal | 9 | 2020 | 7222 | 0.720 |
Why?
|
| Programmed Cell Death 1 Receptor | 4 | 2021 | 1048 | 0.670 |
Why?
|
| Bile Ducts, Intrahepatic | 6 | 2024 | 334 | 0.670 |
Why?
|
| Drug Resistance, Neoplasm | 12 | 2021 | 5178 | 0.620 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2018 | 131 | 0.610 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 3 | 2023 | 371 | 0.610 |
Why?
|
| MicroRNAs | 5 | 2018 | 2947 | 0.600 |
Why?
|
| Genomic Instability | 2 | 2017 | 519 | 0.600 |
Why?
|
| Protein Kinase Inhibitors | 9 | 2023 | 4757 | 0.590 |
Why?
|
| Genes, Tumor Suppressor | 5 | 2023 | 1064 | 0.590 |
Why?
|
| Antigens, CD | 1 | 2021 | 1385 | 0.570 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 6 | 2023 | 1331 | 0.570 |
Why?
|
| Signal Transduction | 12 | 2021 | 11965 | 0.570 |
Why?
|
| Cell Line, Tumor | 21 | 2024 | 14551 | 0.560 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 521 | 0.540 |
Why?
|
| GTP Phosphohydrolases | 1 | 2018 | 336 | 0.540 |
Why?
|
| DNA Copy Number Variations | 3 | 2017 | 1516 | 0.500 |
Why?
|
| Genetic Loci | 2 | 2020 | 481 | 0.500 |
Why?
|
| Genes, APC | 3 | 2009 | 70 | 0.490 |
Why?
|
| Neoplasm Metastasis | 7 | 2018 | 5112 | 0.470 |
Why?
|
| Animals | 35 | 2023 | 59536 | 0.470 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2021 | 1823 | 0.470 |
Why?
|
| Genomics | 5 | 2021 | 2738 | 0.470 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2014 | 135 | 0.460 |
Why?
|
| Systems Biology | 1 | 2013 | 112 | 0.450 |
Why?
|
| Neoplasms | 10 | 2022 | 15193 | 0.440 |
Why?
|
| Mice | 26 | 2023 | 34495 | 0.430 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 907 | 0.420 |
Why?
|
| Gene Expression Regulation, Neoplastic | 11 | 2021 | 8873 | 0.420 |
Why?
|
| Adenomatous Polyposis Coli Protein | 2 | 2009 | 98 | 0.400 |
Why?
|
| High-Throughput Nucleotide Sequencing | 5 | 2022 | 2291 | 0.380 |
Why?
|
| Molecular Targeted Therapy | 4 | 2018 | 2330 | 0.370 |
Why?
|
| Humans | 61 | 2024 | 261506 | 0.370 |
Why?
|
| Genetic Therapy | 1 | 2018 | 1616 | 0.360 |
Why?
|
| Antineoplastic Agents | 10 | 2021 | 14289 | 0.350 |
Why?
|
| Carcinogenesis | 1 | 2016 | 1026 | 0.350 |
Why?
|
| MAP Kinase Signaling System | 6 | 2017 | 848 | 0.330 |
Why?
|
| PTEN Phosphohydrolase | 3 | 2023 | 986 | 0.330 |
Why?
|
| Liver Neoplasms | 3 | 2021 | 4557 | 0.330 |
Why?
|
| Cyclin-Dependent Kinase 6 | 3 | 2018 | 129 | 0.320 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2018 | 1678 | 0.320 |
Why?
|
| Membrane Proteins | 2 | 2018 | 2819 | 0.320 |
Why?
|
| Neoplasm Proteins | 3 | 2020 | 3230 | 0.300 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2009 | 221 | 0.300 |
Why?
|
| Skin Neoplasms | 6 | 2021 | 4654 | 0.300 |
Why?
|
| Gene Expression Profiling | 3 | 2016 | 5159 | 0.290 |
Why?
|
| Glioma | 1 | 2018 | 1963 | 0.290 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2024 | 1546 | 0.290 |
Why?
|
| Immunotherapy | 3 | 2018 | 3341 | 0.270 |
Why?
|
| Lung Neoplasms | 3 | 2021 | 11538 | 0.260 |
Why?
|
| Transforming Growth Factor beta | 5 | 2018 | 1130 | 0.250 |
Why?
|
| Biomarkers, Tumor | 8 | 2024 | 10331 | 0.250 |
Why?
|
| Telomerase | 2 | 2018 | 525 | 0.240 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 2 | 2023 | 96 | 0.230 |
Why?
|
| Databases, Genetic | 2 | 2018 | 745 | 0.230 |
Why?
|
| Brain Neoplasms | 2 | 2018 | 4849 | 0.230 |
Why?
|
| Chromosome Mapping | 1 | 2007 | 1471 | 0.230 |
Why?
|
| Ubiquitin-Specific Proteases | 1 | 2023 | 73 | 0.230 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2007 | 650 | 0.230 |
Why?
|
| Doxycycline | 2 | 2015 | 178 | 0.220 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2024 | 83 | 0.220 |
Why?
|
| Genome | 1 | 2007 | 672 | 0.220 |
Why?
|
| Gene Expression | 3 | 2021 | 3570 | 0.220 |
Why?
|
| V-Set Domain-Containing T-Cell Activation Inhibitor 1 | 1 | 2021 | 29 | 0.210 |
Why?
|
| Biomarkers | 6 | 2022 | 5047 | 0.210 |
Why?
|
| RNA, Long Noncoding | 2 | 2018 | 598 | 0.200 |
Why?
|
| Promoter Regions, Genetic | 3 | 2018 | 3101 | 0.200 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2021 | 76 | 0.200 |
Why?
|
| Receptors, Lysophosphatidic Acid | 1 | 2021 | 80 | 0.200 |
Why?
|
| B7 Antigens | 1 | 2021 | 84 | 0.200 |
Why?
|
| Loss of Function Mutation | 1 | 2021 | 132 | 0.200 |
Why?
|
| Oligonucleotides | 1 | 2022 | 227 | 0.190 |
Why?
|
| Neural Crest | 1 | 2021 | 85 | 0.190 |
Why?
|
| Paraffin Embedding | 1 | 2021 | 226 | 0.190 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2021 | 216 | 0.190 |
Why?
|
| Neoplasm Invasiveness | 4 | 2017 | 3981 | 0.180 |
Why?
|
| Neural Stem Cells | 1 | 2021 | 181 | 0.180 |
Why?
|
| Immunity | 1 | 2022 | 342 | 0.180 |
Why?
|
| Apoptosis | 2 | 2021 | 7591 | 0.180 |
Why?
|
| Myeloid Cells | 1 | 2021 | 269 | 0.170 |
Why?
|
| B7-H1 Antigen | 3 | 2024 | 1022 | 0.170 |
Why?
|
| Adaptation, Biological | 1 | 2019 | 49 | 0.170 |
Why?
|
| Chromosome Inversion | 1 | 2020 | 182 | 0.170 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2022 | 224 | 0.170 |
Why?
|
| Mice, Nude | 4 | 2016 | 4307 | 0.170 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2022 | 3821 | 0.170 |
Why?
|
| Phosphorylation | 5 | 2018 | 4804 | 0.170 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2018 | 15862 | 0.170 |
Why?
|
| Circulating Tumor DNA | 1 | 2022 | 235 | 0.170 |
Why?
|
| Proteins | 1 | 2007 | 1963 | 0.160 |
Why?
|
| Gene Fusion | 1 | 2020 | 209 | 0.160 |
Why?
|
| Genetic Engineering | 2 | 2017 | 288 | 0.160 |
Why?
|
| Gallbladder Neoplasms | 1 | 2020 | 245 | 0.160 |
Why?
|
| Thionucleosides | 1 | 2018 | 12 | 0.160 |
Why?
|
| DNA Mutational Analysis | 2 | 2021 | 2283 | 0.160 |
Why?
|
| Deoxyguanosine | 1 | 2018 | 37 | 0.160 |
Why?
|
| Dimerization | 1 | 2018 | 304 | 0.160 |
Why?
|
| E2F Transcription Factors | 1 | 2018 | 132 | 0.160 |
Why?
|
| Gene Editing | 1 | 2020 | 216 | 0.150 |
Why?
|
| Melanoma, Amelanotic | 1 | 2017 | 9 | 0.150 |
Why?
|
| Mutation Rate | 1 | 2018 | 223 | 0.150 |
Why?
|
| Oxidation-Reduction | 1 | 2019 | 717 | 0.150 |
Why?
|
| DNA Repair | 3 | 2020 | 1872 | 0.150 |
Why?
|
| Transforming Growth Factor beta2 | 1 | 2016 | 32 | 0.150 |
Why?
|
| Fanconi Anemia Complementation Group D2 Protein | 1 | 2016 | 41 | 0.150 |
Why?
|
| Oximes | 2 | 2015 | 175 | 0.150 |
Why?
|
| CRISPR-Cas Systems | 1 | 2020 | 323 | 0.140 |
Why?
|
| Genes, ras | 3 | 2017 | 667 | 0.140 |
Why?
|
| Carcinogens | 1 | 2018 | 384 | 0.140 |
Why?
|
| Neoplasm Transplantation | 3 | 2016 | 1519 | 0.140 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2021 | 1033 | 0.140 |
Why?
|
| MAP Kinase Kinase Kinase 1 | 1 | 2016 | 43 | 0.140 |
Why?
|
| Epigenesis, Genetic | 1 | 2024 | 1399 | 0.140 |
Why?
|
| Pregnancy, Animal | 1 | 2016 | 92 | 0.140 |
Why?
|
| Fatty Acids | 1 | 2019 | 448 | 0.140 |
Why?
|
| Dinoprostone | 1 | 2017 | 208 | 0.140 |
Why?
|
| Enzyme Inhibitors | 2 | 2022 | 1879 | 0.140 |
Why?
|
| Spectrin | 1 | 2016 | 85 | 0.140 |
Why?
|
| Genes, Reporter | 1 | 2018 | 798 | 0.130 |
Why?
|
| Neoplasm, Residual | 1 | 2021 | 1656 | 0.130 |
Why?
|
| Transcriptome | 4 | 2021 | 1859 | 0.130 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2015 | 89 | 0.130 |
Why?
|
| Gene Dosage | 2 | 2016 | 829 | 0.130 |
Why?
|
| Immunohistochemistry | 3 | 2021 | 7548 | 0.130 |
Why?
|
| Mesoderm | 1 | 2017 | 404 | 0.130 |
Why?
|
| Hypoxia | 1 | 2017 | 443 | 0.130 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2016 | 167 | 0.130 |
Why?
|
| Immunomodulation | 1 | 2016 | 242 | 0.120 |
Why?
|
| RNA-Binding Proteins | 1 | 2020 | 984 | 0.120 |
Why?
|
| LIM Domain Proteins | 1 | 2014 | 104 | 0.120 |
Why?
|
| Middle Aged | 8 | 2021 | 86204 | 0.120 |
Why?
|
| Gene Knockdown Techniques | 2 | 2014 | 1077 | 0.120 |
Why?
|
| Colon | 1 | 2017 | 670 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 2 | 2016 | 4367 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 1 | 2021 | 2483 | 0.110 |
Why?
|
| Female | 13 | 2021 | 141928 | 0.110 |
Why?
|
| Transgenes | 1 | 2015 | 557 | 0.110 |
Why?
|
| ROC Curve | 1 | 2016 | 1183 | 0.110 |
Why?
|
| Genes, Essential | 1 | 2012 | 48 | 0.110 |
Why?
|
| Cell Proliferation | 5 | 2021 | 7226 | 0.110 |
Why?
|
| Models, Biological | 2 | 2019 | 3254 | 0.110 |
Why?
|
| Antibodies | 1 | 2015 | 838 | 0.110 |
Why?
|
| Imidazoles | 2 | 2015 | 999 | 0.110 |
Why?
|
| Cancer Vaccines | 1 | 2018 | 697 | 0.110 |
Why?
|
| Prognosis | 8 | 2022 | 21713 | 0.100 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2017 | 973 | 0.100 |
Why?
|
| ErbB Receptors | 1 | 2020 | 2295 | 0.100 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 29902 | 0.100 |
Why?
|
| Chromatin | 1 | 2017 | 942 | 0.100 |
Why?
|
| Membrane Glycoproteins | 1 | 2016 | 1073 | 0.100 |
Why?
|
| Glioblastoma | 2 | 2012 | 1797 | 0.100 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2012 | 278 | 0.100 |
Why?
|
| Tamoxifen | 1 | 2015 | 876 | 0.100 |
Why?
|
| Microfilament Proteins | 1 | 2014 | 487 | 0.100 |
Why?
|
| RNA, Small Interfering | 2 | 2014 | 2216 | 0.090 |
Why?
|
| DNA Methylation | 2 | 2018 | 2669 | 0.090 |
Why?
|
| Neuromuscular Diseases | 1 | 2010 | 63 | 0.090 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2010 | 122 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2010 | 80 | 0.090 |
Why?
|
| Mitochondria | 1 | 2017 | 1282 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 2 | 2017 | 5061 | 0.090 |
Why?
|
| Sequence Deletion | 1 | 2012 | 875 | 0.090 |
Why?
|
| Benzimidazoles | 1 | 2012 | 428 | 0.090 |
Why?
|
| Chromosome Deletion | 1 | 2014 | 1005 | 0.090 |
Why?
|
| Positron-Emission Tomography | 1 | 2018 | 2173 | 0.080 |
Why?
|
| Animals, Genetically Modified | 1 | 2010 | 406 | 0.080 |
Why?
|
| Cytokines | 1 | 2018 | 2809 | 0.080 |
Why?
|
| Nuclear Proteins | 2 | 2017 | 3343 | 0.080 |
Why?
|
| Loss of Heterozygosity | 2 | 2007 | 602 | 0.080 |
Why?
|
| Aged | 5 | 2021 | 70117 | 0.080 |
Why?
|
| Computer Simulation | 1 | 2013 | 1529 | 0.080 |
Why?
|
| Survival Rate | 1 | 2021 | 12221 | 0.080 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2018 | 1763 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2013 | 1085 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2014 | 1493 | 0.080 |
Why?
|
| Genome, Human | 2 | 2020 | 1869 | 0.080 |
Why?
|
| Disease Progression | 4 | 2018 | 6682 | 0.080 |
Why?
|
| Mice, Inbred AKR | 1 | 2007 | 51 | 0.080 |
Why?
|
| Male | 8 | 2021 | 123000 | 0.070 |
Why?
|
| Liver | 1 | 2017 | 2961 | 0.070 |
Why?
|
| Crosses, Genetic | 1 | 2007 | 241 | 0.070 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2007 | 42 | 0.070 |
Why?
|
| Crohn Disease | 1 | 2010 | 351 | 0.070 |
Why?
|
| Tumor Microenvironment | 1 | 2017 | 2864 | 0.070 |
Why?
|
| RNA, Messenger | 1 | 2017 | 6150 | 0.070 |
Why?
|
| Genes, Recessive | 1 | 2007 | 200 | 0.070 |
Why?
|
| Databases, Factual | 1 | 2013 | 2218 | 0.070 |
Why?
|
| DNA-Binding Proteins | 2 | 2017 | 4821 | 0.070 |
Why?
|
| Genetic Techniques | 1 | 2007 | 130 | 0.070 |
Why?
|
| Precision Medicine | 1 | 2013 | 1154 | 0.070 |
Why?
|
| Cell Adhesion | 1 | 2009 | 1008 | 0.070 |
Why?
|
| Adult | 4 | 2021 | 77950 | 0.070 |
Why?
|
| Cell Survival | 1 | 2012 | 3045 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 2054 | 0.070 |
Why?
|
| Cell Adhesion Molecules | 1 | 2009 | 577 | 0.070 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2022 | 1217 | 0.070 |
Why?
|
| Risk Factors | 2 | 2021 | 17523 | 0.070 |
Why?
|
| ras Proteins | 1 | 2010 | 770 | 0.070 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2021 | 6915 | 0.060 |
Why?
|
| Germ-Line Mutation | 1 | 2010 | 1046 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 10035 | 0.060 |
Why?
|
| Sensitivity and Specificity | 3 | 2022 | 4971 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2009 | 15694 | 0.060 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2016 | 460 | 0.060 |
Why?
|
| Young Adult | 1 | 2021 | 21445 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2015 | 3869 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2017 | 5270 | 0.050 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2023 | 170 | 0.050 |
Why?
|
| Mice, Knockout | 1 | 2012 | 5710 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2007 | 661 | 0.050 |
Why?
|
| CTLA-4 Antigen | 2 | 2016 | 657 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2017 | 6942 | 0.050 |
Why?
|
| Liquid Biopsy | 1 | 2022 | 158 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2007 | 1152 | 0.050 |
Why?
|
| Tyrosine | 1 | 2022 | 498 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2023 | 639 | 0.050 |
Why?
|
| Tissue Fixation | 1 | 2021 | 136 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2007 | 1265 | 0.050 |
Why?
|
| Calibration | 1 | 2021 | 337 | 0.050 |
Why?
|
| Chromosome Breakpoints | 1 | 2020 | 104 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2007 | 1439 | 0.050 |
Why?
|
| Sulfonamides | 3 | 2017 | 1823 | 0.050 |
Why?
|
| Indoles | 2 | 2017 | 1009 | 0.050 |
Why?
|
| Genotype | 2 | 2019 | 4109 | 0.050 |
Why?
|
| Clonal Evolution | 1 | 2022 | 253 | 0.040 |
Why?
|
| Retrospective Studies | 4 | 2024 | 37905 | 0.040 |
Why?
|
| CD36 Antigens | 1 | 2019 | 53 | 0.040 |
Why?
|
| PPAR alpha | 1 | 2019 | 62 | 0.040 |
Why?
|
| Bone Morphogenetic Protein 5 | 1 | 2018 | 9 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2021 | 905 | 0.040 |
Why?
|
| Gene Targeting | 1 | 2020 | 292 | 0.040 |
Why?
|
| Colonic Neoplasms | 1 | 2007 | 1390 | 0.040 |
Why?
|
| Microsatellite Instability | 1 | 2020 | 400 | 0.040 |
Why?
|
| Smad Proteins | 1 | 2018 | 88 | 0.040 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2018 | 44 | 0.040 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2018 | 116 | 0.040 |
Why?
|
| RNA | 1 | 2023 | 1013 | 0.040 |
Why?
|
| Homozygote | 2 | 2012 | 717 | 0.040 |
Why?
|
| Adaptor Protein Complex sigma Subunits | 1 | 2017 | 5 | 0.040 |
Why?
|
| Oncogene Protein p55(v-myc) | 1 | 2017 | 19 | 0.040 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2018 | 160 | 0.040 |
Why?
|
| Isotope Labeling | 1 | 2017 | 142 | 0.040 |
Why?
|
| Child | 1 | 2018 | 29154 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2021 | 1869 | 0.040 |
Why?
|
| Fetal Alcohol Spectrum Disorders | 1 | 2016 | 15 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2018 | 265 | 0.040 |
Why?
|
| Cell Surface Extensions | 1 | 2016 | 6 | 0.040 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2017 | 142 | 0.040 |
Why?
|
| Cortactin | 1 | 2016 | 6 | 0.040 |
Why?
|
| SMARCB1 Protein | 1 | 2017 | 109 | 0.040 |
Why?
|
| Genes, Neoplasm | 1 | 2018 | 324 | 0.040 |
Why?
|
| Glycolysis | 1 | 2019 | 519 | 0.040 |
Why?
|
| Lipid Peroxidation | 1 | 2016 | 157 | 0.030 |
Why?
|
| Biological Assay | 1 | 2017 | 177 | 0.030 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2016 | 153 | 0.030 |
Why?
|
| Latent TGF-beta Binding Proteins | 1 | 2015 | 12 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2017 | 548 | 0.030 |
Why?
|
| Cyclin D2 | 1 | 2015 | 40 | 0.030 |
Why?
|
| Wnt Proteins | 1 | 2018 | 397 | 0.030 |
Why?
|
| Proteomics | 1 | 2023 | 1380 | 0.030 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2017 | 204 | 0.030 |
Why?
|
| Catalysis | 1 | 2015 | 250 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2021 | 2084 | 0.030 |
Why?
|
| Genes, myc | 1 | 2017 | 358 | 0.030 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2015 | 92 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2007 | 4549 | 0.030 |
Why?
|
| Vesicular Transport Proteins | 1 | 2016 | 135 | 0.030 |
Why?
|
| Mosaicism | 1 | 2017 | 272 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2016 | 318 | 0.030 |
Why?
|
| Proteolysis | 1 | 2017 | 370 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2017 | 368 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2019 | 1681 | 0.030 |
Why?
|
| Ethanol | 1 | 2016 | 264 | 0.030 |
Why?
|
| Telomere | 1 | 2018 | 505 | 0.030 |
Why?
|
| Receptors, Notch | 1 | 2018 | 383 | 0.030 |
Why?
|
| Hepatectomy | 1 | 2021 | 1011 | 0.030 |
Why?
|
| Histone Demethylases | 1 | 2015 | 144 | 0.030 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2016 | 287 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2010 | 7702 | 0.030 |
Why?
|
| Morpholines | 1 | 2015 | 289 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2021 | 6869 | 0.030 |
Why?
|
| Rats | 2 | 2017 | 6086 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2017 | 6009 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 5395 | 0.030 |
Why?
|
| Aminopyridines | 1 | 2015 | 212 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2016 | 1053 | 0.030 |
Why?
|
| Treatment Outcome | 3 | 2021 | 32848 | 0.030 |
Why?
|
| Actins | 1 | 2016 | 608 | 0.030 |
Why?
|
| Alleles | 1 | 2019 | 2437 | 0.030 |
Why?
|
| Immunoconjugates | 1 | 2016 | 279 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2016 | 582 | 0.030 |
Why?
|
| Aniline Compounds | 1 | 2014 | 177 | 0.030 |
Why?
|
| Phosphonoacetic Acid | 1 | 2012 | 18 | 0.030 |
Why?
|
| Extracellular Matrix | 1 | 2016 | 554 | 0.030 |
Why?
|
| Animals, Newborn | 1 | 2016 | 1338 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2015 | 1313 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2016 | 2307 | 0.030 |
Why?
|
| Pyrimidinones | 1 | 2014 | 314 | 0.030 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2012 | 87 | 0.030 |
Why?
|
| Cell Line | 1 | 2020 | 5114 | 0.030 |
Why?
|
| Transfection | 1 | 2017 | 2944 | 0.030 |
Why?
|
| Pyridones | 1 | 2014 | 348 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 2017 | 1353 | 0.020 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 992 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2012 | 327 | 0.020 |
Why?
|
| Disease Management | 1 | 2016 | 1052 | 0.020 |
Why?
|
| Massachusetts | 1 | 2010 | 106 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2017 | 1121 | 0.020 |
Why?
|
| Hydroxamic Acids | 1 | 2012 | 442 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2021 | 9180 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2010 | 202 | 0.020 |
Why?
|
| Pyridines | 1 | 2016 | 1244 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 4143 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2014 | 1152 | 0.020 |
Why?
|
| DNA Damage | 1 | 2016 | 1954 | 0.020 |
Why?
|
| Cell Movement | 1 | 2016 | 2466 | 0.020 |
Why?
|
| Biopsy | 1 | 2016 | 3443 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2012 | 677 | 0.020 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2010 | 691 | 0.020 |
Why?
|
| Inflammation | 1 | 2017 | 2522 | 0.020 |
Why?
|
| Piperazines | 1 | 2016 | 2101 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2010 | 731 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2010 | 534 | 0.020 |
Why?
|
| Rats, Inbred F344 | 1 | 2007 | 224 | 0.020 |
Why?
|
| Celecoxib | 1 | 2007 | 200 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2015 | 2359 | 0.020 |
Why?
|
| Incidence | 1 | 2016 | 5673 | 0.020 |
Why?
|
| Gene Rearrangement | 1 | 2010 | 783 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 14889 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 3719 | 0.020 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2017 | 1724 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 3552 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2016 | 4078 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2010 | 1442 | 0.020 |
Why?
|
| Comorbidity | 1 | 2010 | 2352 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 13658 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 5319 | 0.010 |
Why?
|
| Pregnancy | 1 | 2016 | 7573 | 0.010 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2007 | 521 | 0.010 |
Why?
|
| Prevalence | 1 | 2010 | 3260 | 0.010 |
Why?
|
| Pyrazoles | 1 | 2007 | 1471 | 0.010 |
Why?
|